16th Conference on Retroviruses and Opportunistic Infections (CROI), 8-11 February 2009, Montreal

30 April 2009. Related: Conference reports, Conference index, CROI 16 (Retrovirus) 2009.

Abstracts and webcasts can be accessed via the conference website at the following link:  http://www.retroconference.org

HTB reports from the conference include:

• HIV infection in the brain: a long-term limitation of HAART?

• When to start HAART – a key research question with the least available data

• Major studies rule out any benefit of Interleukin-2 (IL-2): results from ESPRIT and SILCAAT

• Higher rates of non-AIDS cancers in HIV-positive people

• Effect of breast feeding vs formula feeding on maternal health

• PEPI-Malawi

• Premature delivery and mother-to-child HIV transmission: a risk/benefit analysis among women receiving HAART

• Risk factors for adverse pregnancy outcomes in Botswana

• Higher risk of transmission with delayed control of maternal viral load despite viral loads of <500 copies/mL at delivery

• Lopinavir/r containing regimen superior to nevirapine containing regimen in women previously exposed to single dose nevirapine

• Covering the nevirapine tail

• Effect of single dose nevirapine on subsequent nevirapine-containing HAART: long term outcomes

• High rates of HIV acquisition in pregnancy and post partum in Francistown, Botswana

• Children on HAART do extremely well at South African clinic

• New boosting alternatives to ritonavir: GS-99350 and SPI-452

• Interactions with raltegravir: with twice-daily atazanavir and standard dose lamotrigine

• Effect of tenofovir on abacavir phosphorylation

• Nevirapine: fluconazole and TB treatment

• PI interactions: lopinavir/rifampicin, saquinavir, atazanavir/tenofovir in pregnancy

• Identification of drug interactions in clinical practice

• Effect of substance abuse on ART pharmacokinetics